Skip to content
value.today
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc

🇺🇸 Waltham, Massachusetts, USAPharmaceuticalsFounded 2005
Total raised
$135 M
7 rounds on record
Latest round
$61 M
Aug 2015
First round on record
Jan 2010
Today
Went public
See the company page

Syndax Pharmaceuticals Inc is listed today as Syndax Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Syndax Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2015$61 MNo. 7$50 to $250 million

Syndax Pharmaceuticals Inc: Raise no. 7, Aug 2015

Investors in this round

19 investors had bought by the notice of Aug 28, 2015: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$61 M of $61 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Briggs W Morrison, M.D. · Executive Officer, Director
  • John Pallies · Executive Officer
  • Michael W Metzger · Executive Officer
  • Dennis Podlesak · Director
  • Fabrice Egros, Ph.D. · Director
  • George W Sledge, Jr., M.D. · Director
  • Henry W Chen · Director
  • Ivor Royston, M.D. · Director
  • Kim Kamdar, Ph.D · Director
  • Luke Evnin, Ph.D. · Director
  • Richard P Shea · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Pallies, Chief Financial Officer. Newest notice filed Aug 28, 2015. Read the notice at the SEC.

equitySEC
Jun 2015$24 MNo. 6$10 to $50 million

Syndax Pharmaceuticals Inc: Raise no. 6, Jun 2015

Investors in this round

12 investors had bought by the notice of Jun 15, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $45 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Pallies · Executive Officer
  • Michael W Metzger · Executive Officer
  • Dennis Podlesak · Director
  • Fabrice Egros, Ph.D. · Director
  • George W Sledge, Jr. M.D. · Director
  • Henry W Chen · Director
  • Ivor Royston · Director
  • Kim Kamdar, Ph.D · Director
  • Luke Evnin, Ph.D. · Director
  • Richard P Shea · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Pallies, Chief Financial Officer. Newest notice filed Jun 15, 2015. Read the notice at the SEC.

equitySEC
Feb 2014$2 MNo. 5Under $2 million

Syndax Pharmaceuticals Inc: Raise no. 5, Feb 2014

Investors in this round

3 investors had bought by the notice of Feb 13, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlene Morris · Executive Officer, Director
  • John Pallies · Executive Officer
  • Dennis Podlesak · Director
  • Fabrice Egros, Ph.D. · Director
  • George W Sledge, Jr. M.D. · Director
  • Ivor Royston · Director
  • Kim Kamdar, Ph.D · Director
  • Luke Evnin, Ph.D. · Director
  • Richard P Shea · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arlene Morris, Chief Executive Officer. Newest notice filed Feb 13, 2014. Read the notice at the SEC.

optionsSEC
Jan 2014$1 MNo. 4Under $2 million

Syndax Pharmaceuticals Inc: Raise no. 4, Jan 2014

Investors in this round

4 investors had bought by the notice of Feb 13, 2014: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlene Morris · Executive Officer, Director
  • John Pallies · Executive Officer
  • Dennis Podlesak · Director
  • Fabrice Egros, Ph.D. · Director
  • Ivor Royston · Director
  • Kim Kamdar, Ph.D · Director
  • Luke Evnin, Ph.D. · Director
  • Richard P Shea · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arlene Morris, Chief Executive Officer. Newest notice filed Feb 13, 2014. Read the notice at the SEC.

optionsSEC
Mar 2013$31 MNo. 3$10 to $50 million

Syndax Pharmaceuticals Inc: Raise no. 3, Mar 2013

Investors in this round

18 investors had bought by the notice of Aug 30, 2013: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $48 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlene Morris · Executive Officer, Director · Chief Executive Officer and Director
  • Dennis Podlesak · Director
  • Fabrice Egros · Director
  • Kim Kamdar, Ph.D. · Director
  • Luke Evnin, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arlene Morris, Chief Executive Officer. Newest notice filed Aug 30, 2013. Read the notice at the SEC.

equitySEC
Aug 2010$6 MNo. 2$2 to $10 million

Syndax Pharmaceuticals Inc: Raise no. 2, Aug 2010

Investors in this round

12 investors had bought by the notice of Aug 5, 2010: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joanna Horobin, M.D. · Director, Executive Officer · President and Chief Executive Officer
  • Robert Goodenow, PhD · Executive Officer
  • Dennis Podlesak · Director
  • Kim Kamdar, PhD · Director
  • Rosina Maar Pavia, M.D. · Director
  • Steven St. Peter, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joanna Horobin, M.D., President and Chief Executive Officer. Newest notice filed Aug 5, 2010. Read the notice at the SEC.

debt, optionsSEC
Jan 2010$9 MNo. 1$2 to $10 million

Syndax Pharmaceuticals Inc: Raise no. 1, Jan 2010

Investors in this round

13 investors had bought by the notice of Feb 3, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $16 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joanna Horobin, M.D. · Director, Executive Officer · President and Chief Executive Officer
  • Robert Goodenow, Ph.D. · Executive Officer
  • Dennis Podlesak · Director
  • Kim Kamdar, Ph.D. · Director
  • Rosina Maar Pavia, M.D. · Director
  • Steven St. Peter, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joanna Horobin, M.D., President and Chief Executive Officer. Newest notice filed Feb 3, 2010. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Syndax Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Net product revenue $124.84 million (72%), Collaboration revenue $42.37 million (25%), Milestone revenue $5.14 million (3%).

    Annual report (SEC XBRL) · Dec 2025

  • Syndax Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Aug 2015).

    SEC Form D · Aug 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2015

Products and services#

No products or services of Syndax Pharmaceuticals Inc are on record.

Investors#

No investor of Syndax Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Syndax Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Syndax Pharmaceuticals Inc
NameRoleNamed in
Briggs W Morrison, M.D.Executive officerAug 2015
John PalliesExecutive officerAug 2015
Michael W MetzgerExecutive officerAug 2015
Arlene MorrisExecutive officerFeb 2014
Joanna Horobin, M.D.President and Chief Executive OfficerAug 2010
Robert Goodenow, PhDExecutive officerAug 2010
Robert Goodenow, Ph.D.Executive officerFeb 2010
Briggs W Morrison, M.D.DirectorAug 2015
Dennis PodlesakDirectorAug 2015
Fabrice Egros, Ph.D.DirectorAug 2015
George W Sledge, Jr., M.D.DirectorAug 2015
Henry W ChenDirectorAug 2015
Ivor Royston, M.D.DirectorAug 2015
Kim Kamdar, Ph.DDirectorAug 2015
Luke Evnin, Ph.D.DirectorAug 2015
Richard P SheaDirectorAug 2015
George W Sledge, Jr. M.D.DirectorJun 2015
Ivor RoystonDirectorJun 2015
Arlene MorrisDirectorFeb 2014
Fabrice EgrosDirectorAug 2013
Kim Kamdar, Ph.D.DirectorAug 2013
Joanna Horobin, M.D.President and Chief Executive OfficerAug 2010
Kim Kamdar, PhDDirectorAug 2010
Rosina Maar Pavia, M.D.DirectorAug 2010
Steven St. Peter, M.D.DirectorAug 2010

Went public since 2016. Its SEC number is that of a company listed on a stock exchange.